blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3630839

EP3630839 - BISPECIFIC ANTIBODIES THAT BIND CD 123 CD3 [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.05.2023
Database last updated on 14.06.2024
FormerRequest for examination was made
Status updated on  06.03.2020
FormerThe international publication has been made
Status updated on  08.12.2018
Formerunknown
Status updated on  03.07.2018
Most recent event   Tooltip05.05.2023Application deemed to be withdrawnpublished on 07.06.2023  [2023/23]
Applicant(s)For all designated states
Xencor, Inc.
111 W. Lemon Avenue
Monrovia, CA 91016 / US
[2020/15]
Inventor(s)01 / SAVILLE, Michael, Wayne
c/o Xencor Inc.
111 West Lemon Avenue
Monrovia, CA 91016 / US
02 / FOSTER, Paul
c/o Xencor Inc.
111 West Lemon Avenue
Monrovia, CA 91016 / US
 [2020/15]
Representative(s)Bucher, Tamaris Clare
Novartis Pharma AG
Patent Department
4002 Basel / CH
[2020/15]
Application number, filing date18733114.501.06.2018
[2020/15]
WO2018US35613
Priority number, dateUS201762513763P01.06.2017         Original published format: US 201762513763 P
[2020/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018223002
Date:06.12.2018
Language:EN
[2018/49]
Type: A1 Application with search report 
No.:EP3630839
Date:08.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 06.12.2018 takes the place of the publication of the European patent application.
[2020/15]
Search report(s)International search report - published on:EP06.12.2018
ClassificationIPC:C07K16/28, A61P35/02, A61K39/395
[2020/15]
CPC:
C07K16/2866 (EP,KR,US); A61K39/3955 (EP); A61P35/00 (KR);
A61P35/02 (EP); C07K16/2809 (EP,KR,US); C07K16/2818 (EP,KR,US);
C07K16/2827 (EP,KR,US); A61K2039/505 (EP,KR); A61K2039/507 (EP,KR);
A61K2039/54 (EP,KR); A61K2039/545 (EP,KR,US); C07K2317/31 (EP,KR,US);
C07K2317/73 (EP,KR,US) (-)
C-Set:
A61K39/3955, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/15]
TitleGerman:CD123 UND CD3 BINDENDE BISPEZIFISCHE ANTIKÖRPER[2020/15]
English:BISPECIFIC ANTIBODIES THAT BIND CD 123 CD3[2020/15]
French:ANTICORPS BISPÉCIFIQUES LIANT CD123 CD3[2020/15]
Entry into regional phase02.01.2020National basic fee paid 
02.01.2020Designation fee(s) paid 
02.01.2020Examination fee paid 
Examination procedure02.01.2020Examination requested  [2020/15]
02.01.2020Date on which the examining division has become responsible
09.07.2020Amendment by applicant (claims and/or description)
03.01.2023Application deemed to be withdrawn, date of legal effect  [2023/23]
31.01.2023Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2023/23]
Fees paidRenewal fee
15.06.2020Renewal fee patent year 03
14.06.2021Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.06.202205   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2016028896  (NOVARTIS AG [CH], et al) [A] 1-32 * page 2, line 21 - line 30; examples 1-3,8 *;
 [Y]WO2016079050  (HOFFMANN LA ROCHE [CH], et al) [Y] 1-32 * page 49, line 3 - line 21 * * page 51, line 3 - page 52, line 14 * * page 94, line 1 - page 108, line 11 * * example 50 *;
 [YD]WO2016182751  (XENCOR INC [US]) [YD] 1-32 * paragraphs [0404] - [0416]; example 3; claims 1-52,63-72 *;
 [IP]WO2017210443  (XENCOR INC [US]) [IP] 1-32 * the whole document, in particular examples 1-3 *;
 [XP]WO2017214092  (MACROGENICS INC [US]) [XP] 1-13* paragraphs [0299] , [0377] - [0381] - [0397] , [0403] , [0313] - [0315] - [0423] - [0433] - [0439]; claims 1-18 *;
 [Y]  - XIAOLONG ZHANG ET AL, "The development of bispecific antibodies and their applications in tumor immune escape", EXPERIMENTAL HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON, UK, (20170502), vol. 6, no. 1, doi:10.1186/S40164-017-0072-7, pages 1 - 6, XP021244861 [Y] 1-32 * the whole document, in particular table 1, page 4, right-hand column, 2nd paragraph and conclusion *

DOI:   http://dx.doi.org/10.1186/s40164-017-0072-7
 [Y]  - KRUPKA C ET AL, "Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism", LEUKEMIA, BASINGSTOKE : NATURE PUBLISHING GROUP, (20150804), vol. 30, no. 2, ISSN 1476-5551, pages 484 - 491, XP002763683 [Y] 1-32 * the whole document, in particular introduction, page 487, right-hand column-page 488, left-hand column, bridging paragraph, discussion *
 [Y]  - OSADA T ET AL, "CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 64, no. 6, doi:10.1007/S00262-015-1671-Y, ISSN 1432-0851, (20150601), pages 677 - 688, (20150306), XP002753474 [Y] 1-32 * abstract * * page 678, column l, paragraph 2 - column r, paragraph 3 * * page 680, column r, paragraph 3 - page 684, column r, paragraph 1 * * page 685, column l, paragraph 1 - page 687, column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1007/s00262-015-1671-y
 [Y]  - Masarova L et al, "Immune Checkpoint Approaches in AML and MDS: A Next Frontier?", The Journal of Targeted Therapies in Cancer, (20170306), URL: https://www.targetedonc.com/printer?url=/publications/targeted-therapies-cancer/2017/2017-february/immune-checkpoint-approaches-in-aml-and-mds-a-next-frontier, (20180821), XP002784099 [Y] 1-32 * the whole document, in particular last paragraph *
by applicantFR90165E
 US5811097
 WO9848032
 WO9920758
 WO9940196
 US6111090
 WO0103720
 US6586207
 WO03073238
 US6689607
 WO2004060319
 US2004214988
 WO2005007190
 WO2005035727
 WO2005055808
 WO2005074524
 WO2005115451
 US7025962
 WO2006083289
 WO2006121168
 WO2007005874
 WO2007133822
 EP1866339
 EP0920505
 WO2009101611
 WO2009114335
 US7618632
 WO2010003118
 US2010028330
 WO2010019570
 WO2010027827
 WO2010077634
 US7812135
 WO2011028683
 WO2011051726
 US7943743
 WO2011066342
 US2011150892
 WO2011090754
 US8008449
 WO2011155607
 US2012039906
 US2012114649
 US8354509
 US8388967
 WO2013039954
 EP2581113
 WO2013079174
 EP1947183
 US8552156
 US8586023
 US8591886
 US8609089
 WO2014008218
 WO2014012479
 US2014044728
 US2014072566
 US8709424
 WO2014145806
 US2014288275
 US2014294823
 WO2015026684
 WO2015034820
 US2015210769
 US2015218274
 US2015259420
 US2015307629
 US2016108123
 WO2016086189
 WO2016182751
    - CHAMES; BATY, mAbs, (20090000), vol. 1, no. 6, pages 1 - 9
    - HOLLIGER; HUDSON, Nature Biotechnology, (20050000), vol. 23, no. 9, pages 1126 - 1136
    - KONTERMANN, mAbs, (20120000), vol. 4, no. 2, page 182
    - MILSTEIN et al., Nature, (19830000), vol. 305, pages 537 - 540
    - WU et al., Nature Biotechnology, (20070000), vol. 25, no. 11, pages 1290 - 1297
    - MICHAELSON et al., mAbs, (20090000), vol. 1, no. 2, pages 128 - 141
    - ZUO et al., Protein Engineering, (20000000), vol. 13, no. 5, pages 361 - 367
    - SHEN et al., J Biol Chem, (20060000), vol. 281, no. 16, pages 10706 - 10714
    - LU et al., J Biol Chem, (20050000), vol. 280, no. 20, pages 19665 - 19672
    - BOWLES; WEINER, J Immunol Methods, (20050000), vol. 304, pages 88 - 99
    - HEYMAN, Immunol Lett, (20030000), vol. 88, no. 2, pages 157 - 161
    - SMITH; CLATWORTHY, Nature Reviews Immunology, (20100000), vol. 10, pages 328 - 343
    - KUHNS et al., Immunity, (20060000), vol. 24, pages 133 - 139
    - PERRUCHE et al., J Immunol, (20090000), vol. 183, no. 2, pages 953 - 61
    - CHATENOUD; BLUESTONE, Nature Reviews Immunology, (20070000), vol. 7, pages 622 - 632
    - "Genbank", Database accession no. NM_000073
    - "Genbank", Database accession no. MP_000064
    - "Genbank", Database accession no. NM 000732
    - "Genbank", Database accession no. NM_001040651
    - "Genbank", Database accession no. NP _00732
    - "Genbank", Database accession no. NP_001035741
    - "Genbank", Database accession no. NM_000733
    - "Genbank", Database accession no. NP_00724
    - "Genbank", Database accession no. NM_001267713
    - "Genbank", Database accession no. NM 002183
    - "Genbank", Database accession no. NP_001254642
    - "Genbank", Database accession no. NP_002174
    - EDELMAN et al., Proc Natl Acad Sci USA, (19690000), vol. 63, pages 78 - 85
    - J. W. CHIN et al., Journal of the American Chemical Society, (20020000), vol. 124, pages 9026 - 9027
    - J. W. CHIN; P. G. SCHULTZ, ChemBioChem, (20020000), vol. 11, pages 1135 - 1137
    - J. W. CHIN et al., PICAS United States of America, (20020000), vol. 99, pages 11020 - 11024
    - L. WANG; P. G. SCHULTZ, Chem., (20020000), pages 1 - 10
    - SIMON et al., PNAS USA, (19920000), vol. 89, no. 20, page 9367
    - CROPP; SHULTZ, Trends Genet., (20040000), vol. 20, no. 12, pages 625 - 30
    - ANDERSON et al., Proc Natl Acad Sci USA, (20040000), vol. 101, no. 2, pages 7566 - 71
    - CHIN et al., Science, (20030000), vol. 301, no. 5635, pages 964 - 7
    - DAVIS et al., Immunological Reviews, (20020000), vol. 190, pages 123 - 136
    - JEFFERIS et al., Immunol Lett, (20020000), vol. 82, pages 57 - 65
    - IZUMOTO et al., J Neurosurg, (20080000), vol. 108, pages 963 - 971
    - CHEMICAL ABSTRACTS, Database accession no. 946414-94-4
    - HAMID, O. et al., New England Journal of Medicine, (20130000), vol. 369, no. 2, pages 134 - 44
    - CHEMICAL ABSTRACTS, Database accession no. 477202-00-9
 US20010865198
 WO2005US25472
 WO2008US74693
 US20090477711
 WO2015US62772
 WO2016US29797
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.